Home Categories (S)-(+)-Ibuprofen
A7405012

(S)-(+)-Ibuprofen , >98.0%(GC) , 51146-56-6

Synonym(s):
(S)-(+)-2-(4-Isobutylphenyl)propionic acid;(S)-(+)-4-Isobutyl-α-methylphenylacetic acid;S-(+)-IBU

CAS NO.:51146-56-6

Empirical Formula: C13H18O2

Molecular Weight: 206.28

MDL number: MFCD00069289

EINECS: 610-620-9

Pack Size Price Stock Quantity
1G RMB28.80 In Stock
5G RMB36.00 In Stock
25G RMB115.20 In Stock
100G RMB434.40 In Stock
500g RMB2062.40 In Stock
others     Enquire
Update time: 2022-07-08

PRODUCT Properties

Melting point: 49-53 °C(lit.)
alpha  57 º (c=2, EtOH)
Boiling point: 285.14°C (rough estimate)
Density  1.0364 (rough estimate)
refractive index  59 ° (C=2, EtOH)
Flash point: >230 °F
storage temp.  Sealed in dry,Room Temperature
solubility  45% (w/v) aq 2-hydroxypropyl-β-cyclodextrin: 1.5 mg/mL
pka 4.41±0.10(Predicted)
form  solid
color  white
optical activity [α]20/D +59°, c = 2 in ethanol
Water Solubility  insoluble
BRN  3590022
Stability: Stable. Incompatible with strong oxidizing agents.
InChIKey HEFNNWSXXWATRW-JTQLQIEISA-N
CAS DataBase Reference 51146-56-6(CAS DataBase Reference)

Description and Uses

Dexibuprofen, the S-(+)-isomer of the widely used NSAID agent ibuprofen, was launched in Austria for the treatment of rheumatoid arthritis. While the racemic compound is commonly used clinically, the antiinflammatory activity is mediated via the S-isomer by inhibition of prostaglandin synthesis. It has also been demonstrated that the R-isomer is converted to the Santipode in vivo via a CoA thioester intermediate. Since CoA plays a pivotal role in intermediary metabolism and maintenance of the [acyl-CoA], generation of R-ibuprofen-CoA competitively inhibits many CoA-dependent reactions, which consequently produces perturbations of hepatocyte Intermediary metabolism and mitocondrial function. Pure S-ibuprofen usage, therefore, is preferred allowing a reduction in dosage level and an improved side effect profile.

Ibuprofen is a non-steroidal anti-inflammatory drug with diverse biochemical actions, most notably inhibiting COX-1 and COX-2 (IC50s = 2.6 and 1.53, μM, respectively). It is commonly synthesized as a racemic mixture of (S)- and (R)-isomers. (S)-Ibuprofen is an enantiomer that more potently inhibits COX activity, thromboxane formation, and platelet aggregation than the (R)-form. (S)-Ibuprofen also inhibits activation of NF-κB more effectively than (R)-ibuprofen (IC50s = 62 and 122 μM, respectively). However, the enantiomers are equipotent in blocking superoxide formation, β-glucuronidase release, and LTB4 generation by stimulated neutrophils (IC50 values range from 0.14 to 0.58 μM). A majority of (R)-ibuprofen can be inverted to (S)-ibuprofen in humans after oral administration.

Safety

Symbol(GHS) 
GHS07
Signal word  Warning
Hazard statements  H315-H319
Precautionary statements  P264-P280-P302+P352+P332+P313+P362+P364-P305+P351+P338+P337+P313
Hazard Codes  Xn
Risk Statements  63-22
Safety Statements  45-36/37
WGK Germany  3
HS Code  29163990

RELATED PRODUCTS